Literature DB >> 34752333

Strategies for targeting cell surface proteins using multivalent conjugates and chemical biology.

Shivani Sachdev1, Chino C Cabalteja1, Ross W Cheloha2.   

Abstract

Proper function of receptors on the cell surface is essential for homeostasis. Compounds that target cell surface receptors to address dysregulation have proven exceptionally successful as therapeutic agents; however, the development of compounds with the desired specificity for receptors, cells, and tissues of choice has proven difficult in some cases. The use of compounds that can engage more than one binding site at the cell surface offers a path toward improving biological specificity or pharmacological properties. In this chapter we summarize historical context for the development of such bivalent compounds. We focus on developments in chemical methods and biological engineering to provide bivalent compounds in which the high affinity and specificity of antibodies are leveraged to create multifunctional conjugates with new and useful properties. The development of methods to meld biological macromolecules with synthetic compounds will facilitate modulation of receptor biology in ways not previously possible.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antibody; Antibody-drug conjugate; Bispecific; Chemical biology; GPCR; Nanobody; Receptor; VHH

Mesh:

Substances:

Year:  2021        PMID: 34752333      PMCID: PMC8895325          DOI: 10.1016/bs.mcb.2021.06.004

Source DB:  PubMed          Journal:  Methods Cell Biol        ISSN: 0091-679X            Impact factor:   1.829


  70 in total

1.  Heterodimers of alpha1B- and alpha1D-adrenergic receptors form a single functional entity.

Authors:  Chris Hague; Sarah E Lee; Zhongjian Chen; Steven C Prinster; Randy A Hall; Kenneth P Minneman
Journal:  Mol Pharmacol       Date:  2005-09-29       Impact factor: 4.436

Review 2.  G Protein-Coupled Receptor Heteromers.

Authors:  Ivone Gomes; Mohammed Akli Ayoub; Wakako Fujita; Werner C Jaeger; Kevin D G Pfleger; Lakshmi A Devi
Journal:  Annu Rev Pharmacol Toxicol       Date:  2015-10-22       Impact factor: 13.820

3.  Highly Selective Dopamine D3 Receptor (D3R) Antagonists and Partial Agonists Based on Eticlopride and the D3R Crystal Structure: New Leads for Opioid Dependence Treatment.

Authors:  Vivek Kumar; Alessandro Bonifazi; Michael P Ellenberger; Thomas M Keck; Elie Pommier; Rana Rais; Barbara S Slusher; Eliot Gardner; Zhi-Bing You; Zheng-Xiong Xi; Amy Hauck Newman
Journal:  J Med Chem       Date:  2016-08-10       Impact factor: 7.446

4.  Narcotic antagonistic potency of bivalent ligands which contain beta-naltrexamine. Evidence for bridging between proximal recognition sites.

Authors:  M Erez; A E Takemori; P S Portoghese
Journal:  J Med Chem       Date:  1982-07       Impact factor: 7.446

Review 5.  Targeting receptor complexes: a new dimension in drug discovery.

Authors:  Mette Ishøy Rosenbaum; Louise S Clemmensen; David S Bredt; Bernhard Bettler; Kristian Strømgaard
Journal:  Nat Rev Drug Discov       Date:  2020-11-11       Impact factor: 84.694

6.  Discovery of the First Selective M4 Muscarinic Acetylcholine Receptor Antagonists with in Vivo Antiparkinsonian and Antidystonic Efficacy.

Authors:  Mark S Moehle; Aaron M Bender; Jonathan W Dickerson; Daniel J Foster; Aidong Qi; Hyekyung P Cho; Yuping Donsante; Weimin Peng; Zoey Bryant; Kaylee J Stillwell; Thomas M Bridges; Sichen Chang; Katherine J Watson; Jordan C O'Neill; Julie L Engers; Li Peng; Alice L Rodriguez; Colleen M Niswender; Craig W Lindsley; Ellen J Hess; P Jeffrey Conn; Jerri M Rook
Journal:  ACS Pharmacol Transl Sci       Date:  2021-08-02

7.  Engineering of a GLP-1 analogue peptide/anti-PCSK9 antibody fusion for type 2 diabetes treatment.

Authors:  Matthieu Chodorge; Anthony J Celeste; Joseph Grimsby; Anish Konkar; Pia Davidsson; David Fairman; Lesley Jenkinson; Jacqueline Naylor; Nicholas White; Jonathan C Seaman; Karen Dickson; Benjamin Kemp; Jennifer Spooner; Emmanuel Rossy; David C Hornigold; James L Trevaskis; Nicholas J Bond; Timothy B London; Andrew Buchanan; Tristan Vaughan; Cristina M Rondinone; Jane K Osbourn
Journal:  Sci Rep       Date:  2018-12-03       Impact factor: 4.379

8.  Novel and Potent Dopamine D2 Receptor Go-Protein Biased Agonists.

Authors:  Alessandro Bonifazi; Hideaki Yano; Adrian M Guerrero; Vivek Kumar; Alexander F Hoffman; Carl R Lupica; Lei Shi; Amy Hauck Newman
Journal:  ACS Pharmacol Transl Sci       Date:  2019-01-14

9.  Improved GPCR ligands from nanobody tethering.

Authors:  Ross W Cheloha; Fabian A Fischer; Andrew W Woodham; Eileen Daley; Naomi Suminski; Thomas J Gardella; Hidde L Ploegh
Journal:  Nat Commun       Date:  2020-04-29       Impact factor: 14.919

10.  Structure-guided Discovery of Dual-recognition Chemibodies.

Authors:  Alan C Cheng; Elizabeth M Doherty; Sheree Johnstone; Erin F DiMauro; Jennifer Dao; Abhinav Luthra; Jay Ye; Jie Tang; Thomas Nixey; Xiaoshan Min; Philip Tagari; Les P Miranda; Zhulun Wang
Journal:  Sci Rep       Date:  2018-05-15       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.